Curis Inc.’s 1-for-20 Reverse Split Raises Liquidity Concerns and Odd-Lot Trading RisksTip Ranks·2 days ago, 01:01 AMCRIS-2.78%
CRIS: Net loss increased, cash runway is short, and additional funding is urgently needed to sustain operationsQuartr·Aug 14 at 03:25 PMCRIS-2.78%
Curis FY26 Q2 net loss widens 71% to $32.78 million vs FY25; revenue posts no revenue vs FY25PUBT·Aug 14 at 03:07 PMCRIS-2.78%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Aug 13 at 07:05 AMABEO+0.59%NRC+3.10%
Curis prices USD 5.6 million public offering at USD 1.5 per share with warrantsPUBT·Aug 13 at 07:02 AMCRIS-2.78%
Pre-market hot trades in US stocks: Bimergen Energy up 8.27% pre-market; Curis up 8.23% pre-marketPrice Alert·Aug 12 at 07:43 AMBESS-6.51%CRIS-2.78%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Aug 11 at 12:06 PMALMR+4.19%GRI0.00%
Curis regains Nasdaq bid-price compliance, remains under one-year panel monitorPUBT·Jul 30 at 03:05 PMCRIS-2.78%
Curis doses first five patients in TakeAim CLL combo trial of emavusertib, zanubrutinibPUBT·Jul 30 at 07:07 AMCRIS-2.78%
09:03 ETAssureCare® and CURIS Partner to Ensure RHT Funding Builds Infrastructure That Outlasts the Programprnewswire·Jul 27 at 08:03 AMCRIS-2.78%
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focusbenzinga_article·Jul 24 at 01:03 PMCRIS-2.78%
Curis notifies press release availability on positive emavusertib updatePUBT·Jul 22 at 06:04 AMCRIS-2.78%
